Bo Chen, Katherine A Vousden, Brian Naiman, Sean Turman, Hong Sun, Shu Wang, Lisa M K Vinall, Benjamin P Kemp, Srinath Kasturiangan, D Gareth Rees, Ethan Grant, Mary Jane Hinrichs, Steven Eck, Antonio DiGiandomenico, M Jack Borrok, Martin J Borrok, Neang Ly, Ximing Xiong, Carlos Gonzalez, Christopher Morehouse, Yue Wang, Yebin Zhou, Jennifer Cann, Weiguang Zhao, Holly Koelkebeck, Koshu Okubo, Tanya N Mayadas, David Howe, Janet Griffiths, Roland Kolbeck, Ronald Herbst, Gary P Sims
OBJECTIVE: Immune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) VIB9600 (previously known as MEDI9600) that blocks IgG immune complex-mediated cellular activation for clinical development. METHODS: VIB9600 was humanised and optimised from the IV.3 Ab. Binding affinity and specificity were determined by Biacore and ELISA. Confocal microscopy, Flow Cytometry-based assays and binding competition assays were used to assess the mode of action of the antibody...
November 20, 2018: Annals of the Rheumatic Diseases